Vitiligo vulgaris is an autoimmune pigmentary disorder with no universally efficacious therapeutic options.
Separate applications of calcipotriene ointment 0.005% and topical corticosteroid ointments have been successful in the repigmentation of vitiligo.
We sought to examine the efficacy of a combination calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment in the repigmentation of vitiligo.
An institutional review board-approved retrospective chart review was conducted in 13 pediatric and adult patients with vitiligo treated with calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment once daily for at least 2 months.
Two of 3 children had 76% to 100% repigmentation of facial vitiligo with once-daily usage after 2 months.
Of the 10 adults (aged 28-55 years), 1 had 100% facial repigmentation in 3 months, 1 had 76% to 99% facial repigmentation in 5 to 9 months, and 2 had 26% to 50% repigmentation in 3 months.
Twelve patients developed some facial repigmentation.
No patients experienced atrophy, telangiectases, or lesion enlargement during treatment.
Combination calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment shows promise as a once-daily vitiligo therapy.
Adult and pediatric facial vitiligo patients may see repigmentation as early as 2 months after initiation of therapy.
Children may experience a better response, but larger studies are needed.
2012-01-25
Eng.
Cutis; cutaneous medicine for the practitioner
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025, USA.
Cutis. 2011 Nov;88(5):256-9
© Galenicom 1999-2013